Standard systemic therapy

Phase 3

Standard systemic therapy is one of 2 therapeutic programs targeting Gastric Cancer Peritoneal Metastases. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

Gastric Cancer Peritoneal MetastasesRecruiting

Gastric Cancer Peritoneal MetastasesPhase 3

Recruiting

Competition

Competitive Landscape

1 competitor in Gastric Cancer Peritoneal Metastases

#DrugCompanyPhaseTrials

Intraperitoneal Paclitaxel

EECOG-ACRIN Cancer Research Group

Phase 3

1 2

Standard systemic therapy

MMagnus Nilsson

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2031

Phase 3Recruiting

Gastric Cancer Peritoneal Metastases

NCT07304271

Clinical

Trials by Indication[1]

Gastric Cancer Peritoneal Metastases1 trial

Randomised Phase III Trial of First Line Intraperitoneal Paclitaxel and Systemic Therapy Versus Systemic Therapy Alone in Gastric Cancer Patients With Peritoneal Metastases - IPa-Gastric

Recruiting·MMagnus Nilsson·Phase 3·NCT07304271·262 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Standard systemic therapy. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for Standard systemic therapy. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Magnus Nilsson company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 3[1]
Company: MMagnus Nilsson

Standard systemic therapy

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q1 2031

Trials by Indication[1]

Gastric Cancer Peritoneal Metastases1 trial

References

Drug Info

Quick Facts

Related News